Skip Navigation LinksHome > June 2010 - Volume 29 - Issue 6 > Randomized Trial to Determine Safety and Immunogenicity of T...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181d285c7
Original Studies

Randomized Trial to Determine Safety and Immunogenicity of Two Strategies for Hepatitis B Vaccination in Healthy Urban Adolescents in the United States

Cunningham, Coleen K. MD*; Rudy, Bret J. MD†; Xu, Jiahong MS, MPH‡; Bethel, James PhD‡; Kapogiannis, Bill G. MD§; Ahmad, Sushma MB BS‡; Wilson, Craig M. MD¶; Flynn, Patricia M. MD∥; the Adolescent Medicine Trials Network for HIV/AIDS Interventions

Supplemental Author Material
Collapse Box

Abstract

Background: Multiple studies have shown excellent response rates after hepatitis B immunization in youth; however, one previous study conducted in urban youth demonstrated poor responses.

Methods: Urban youth, ages 12 to 17 years, at participating Adolescent Medicine Trials Network for HIV/AIDS Interventions Clinical/Research sites were randomized to receive either 2 doses of Recombivax HB (10 μg hepatitis B surface antigen) or Twinrix (20 μg hepatitis B surface antigen and 720 EL.U hepatitis A antigen) at 0 and 24 weeks. Safety data were collected and antibody measures performed at 0, 28, and 76 weeks.

Results: A total of 123 subjects were enrolled and 102 had week 28 serum samples available for antibody measure. A positive response (serum antibody ≥10 mIU/mL) to hepatitis B antigen was documented in 41 of 47 (87.2%; 95% confidence interval [CI] 74.3%–95.2%) Recombivax HB recipients and in 52 of 55 (94.6%; 95% CI, 84.9%–98.9%) Twinrix recipients (P = 0.295). In an adjusted analysis, those identified as Hispanic ethnicity (N = 86) were more likely to have a positive response (odds ratio 7.38, 95% CI, 1.56–34.95; P = 0.0018); whereas those who identified as not heterosexual (N = 9) were less likely to respond (odds ratio = 0.12, 95% CI, 0.02–0.74). The majority of youth in the Twinrix arm were hepatitis A antibody positive at baseline (26/51; 51%); however, 24 of 25 hepatitis A antibody negative youth responded to the hepatitis A component. Both vaccines were safe.

Conclusions: Response rate to 2 doses of Recombivax HB in urban youth is lower than previous studies suggest. The factors associated with diminished response are not known.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.